[Targeted therapies in thoracic oncology].
Fiche publication
Date publication
juin 2004
Journal
Revue des maladies respiratoires
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle
Tous les auteurs :
Quoix E, Beau-Faller M, Douillard JY, Milleron B
Lien Pubmed
Résumé
Better understanding of the alterations of cellular physiology during carcinogenesis has resulted in the development of new anticancer agents called biological targeted therapies. These therapies will probably complement the traditional treatments (surgery, radiotherapy and chemotherapy).
Mots clés
Alkyl and Aryl Transferases, antagonists & inhibitors, Cyclooxygenase 2, Farnesyltranstransferase, Humans, Isoenzymes, antagonists & inhibitors, Lung Neoplasms, drug therapy, Membrane Proteins, Metalloproteases, antagonists & inhibitors, Neovascularization, Pathologic, Prostaglandin-Endoperoxide Synthases, Receptors, Vascular Endothelial Growth Factor, antagonists & inhibitors, Signal Transduction
Référence
Rev Mal Respir. 2004 Jun;21(3 Pt 1):527-37